Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.

 

We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field. They represent the entire oncology value chain, doing everything from exploratory research to selling therapeutics and diagnostics to global markets.

 

Norwegian Centre of Expertise
In 2007, we became a Norwegian Centre of Expertise. Since then, we have developed into a strong biotech cluster well positioned in the global oncology industry. The world class research environment in immunotherapy and the presence of several IT-companies, strengthen the cluster’s position as a global knowledge and innovation centre.

 

Our Incubator Environment
Around 30 of the members are gathered in the Oslo Cancer Cluster Incubator, a successful biotech cluster, situated in the Oslo Cancer Cluster Innovation Park. We share the innovation park with Ullern Upper Secondary School, the Cancer Registry of Norway and Oslo University Hospital.

Next door is the leading comprehensive cancer hospital in Northern Europe, Oslo University Hospital Radiumhospitalet, and its Institute for Cancer Research. We collaborate closely with them, and we have a long-term school-industry collaboration with Ullern Upper Secondary.

 

Immuno-Oncology
A growing number of members in the cluster develop novel cancer immunotherapies. Therefore, we established the Norwegian Immuno-Oncology Consortium in 2013. The goal of the consortium is to strengthen the knowledge-base and expertise, and to facilitate more national and international collaboration within immuno-oncology. The consortium also addresses precision medicine.

 

Precision Medicine
Healthcare is becoming digitised. New technology, including tumour sequencing, is generating vast amounts of data that need to be sorted and analysed. This has opened for IT-companies to take part in developing personalised medicine, tailoring drugs to the biology of each patient.

We use global connections and national advantages to help get the right treatment to the right patient at the right time. New technology helps us. Software companies, like IBM Watson and SAS Institute, are part of our cluster. We are part of EU projects such as  PERMIDES, and of collaborations with technological research facilities such as the Lawrence Livermore National Laboratory in the US and the Cancer Registry of Norway.

Oslo Cancer Cluster initiated National Cancer Genomic Consortium in 2012. It consists of clinicians and specialised cancer research groups collaborating on two large research projects that aim to establish new clinical practises for cancer treatment.

 

Print This Page